Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Notes Payables (2022 - 2026)

HeartSciences (HSCS) has disclosed Notes Payables for 4 consecutive years, with $500000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Notes Payables fell 78.87% year-over-year to $500000.0, compared with a TTM value of $500000.0 through Oct 2025, down 78.87%, and an annual FY2025 reading of $2.6 million, up 410.23% over the prior year.
  • Notes Payables was $500000.0 for Q4 2025 at HeartSciences, down from $1.5 million in the prior quarter.
  • Across five years, Notes Payables topped out at $2.6 million in Q2 2025 and bottomed at $130000.0 in Q3 2022.
  • Average Notes Payables over 4 years is $1.1 million, with a median of $815000.0 recorded in 2022.
  • Peak annual rise in Notes Payables hit 410.23% in 2025, while the deepest fall reached 78.87% in 2025.
  • Year by year, Notes Payables stood at $1.1 million in 2022, then grew by 25.41% to $1.4 million in 2023, then skyrocketed by 67.01% to $2.4 million in 2024, then tumbled by 78.87% to $500000.0 in 2025.
  • Business Quant data shows Notes Payables for HSCS at $500000.0 in Q4 2025, $1.5 million in Q3 2025, and $2.6 million in Q2 2025.